Clinical Trials in Alessandria, Italy
1 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
ETOP IBCSG Partners Foundation390 enrolled34 locationsNCT06931717
Recruiting
Phase 3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ETOP IBCSG Partners Foundation290 enrolled42 locationsNCT06284317
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Unresectable Pleural Mesothelioma
AstraZeneca825 enrolled178 locationsNCT06097728
Recruiting
Phase 1Phase 2
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company720 enrolled67 locationsNCT05768139
Recruiting
Phase 1
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Non-small Cell Lung CancerThoracic Tumors
Amgen500 enrolled83 locationsNCT06333951
Recruiting
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Novartis Pharmaceuticals300 enrolled32 locationsNCT07093801
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled214 locationsNCT07128199
Recruiting
Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure GmbH734 enrolled90 locationsNCT06216301
Recruiting
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
MesotheliomaMesotheliomas PleuralMesothelioma; Lung
Istituto Oncologico Veneto IRCCS220 enrolled10 locationsNCT06581549
Recruiting
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
Pleural Mesothelioma
NovoCure Ltd.198 enrolled23 locationsNCT05538806
Recruiting
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Follicular Lymphoma
Fondazione Italiana Linfomi - ETS56 enrolled14 locationsNCT06070961
Recruiting
Phase 3
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Mesotheliomas Pleural
Gruppo Oncologico Italiano di Ricerca Clinica162 enrolled19 locationsNCT04996017
Recruiting
Timisnar - Biomarkers Substudy (Timisnar-mirna)
Rectal Cancer
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria200 enrolled1 locationNCT03962088
Recruiting
Neutrophil-to-Lymphocite Ratio (NLR) and C-reactive Protein (CRP) as New Markers in Diagnosis and Prediction of Colorectal Cancer
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria100 enrolled2 locationsNCT05129046